Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target MaintainedTip Ranks·Jul 21 at 02:23 PMANAB-1.38%
Is AnaptysBio (ANAB) Undervalued As Russell Index Deletions Reshape Trading Flows?Simplywall·Jul 6 at 11:06 AMANAB-1.38%
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?Simplywall·Jun 30 at 10:51 AMANAB-1.38%
AnaptysBio subleases 45,057 sq ft San Diego office space to First Tracks BiotherapeuticsPUBT·Jun 22 at 03:06 PMTRAX-5.63%ANAB-1.38%
AnaptysBio posts Form 8937 on tax treatment of First Tracks spin-off dividendTradingView·May 29 at 03:23 PMANAB-1.38%TRAX-5.63%
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price GainsSimplywall·May 27 at 12:31 PMANAB-1.38%
AnaptysBio (NASDAQ:ANAB) Trading Down 7.7% After Earnings MissMarket Beat·May 13 at 09:11 AMANAB-1.38%
Anaptysbio | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 25.56 MEarnings Watch·May 12 at 03:31 PMANAB-1.38%
Anaptysbio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 25.56 MEarnings Watch·May 12 at 03:31 PMANAB-1.38%
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update | ANAB Stock NewsStockTitan·May 12 at 07:40 AMANAB-1.38%
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors | ANAB Stock NewsStockTitan·May 11 at 12:15 AMANAB-1.38%
